… Lung cancer is the most common cause of cancer deaths. … However, with the understanding
of lung cancer biology, and … non–small-cell lung cancer (NSCLC). Epidermal growth factor …

… , already registered for the treatment of advanced breast cancer and currently under
investigation in non-small-cell lung cancer [20]. In lung cancer, growth inhibition with trastuzumab …

… Epidermal Growth Factor Receptor in Non–Small-cell Lung Cancer Lung cancer develops
… and genetic defects have been identified in lung cancer, but a clear understanding of the …

… A number of newer inhibitors are currently in clinical development with … receptor inhibition.
These include monoclonal antibodies, such as panitumumab and matuzumab; dual inhibitors …

… -cell lung cancer (NSCLC) is the leading cause of cancer-related … In particular, the epidermal
growth-factor receptor superfamily … Several selective inhibitors of this family of receptors are …

… Lung cancer is the leading cause of cancer-related deaths worldwide, … the USA, lung cancer
accounts for approximately 28% of all cancer-related deaths [2]. Non-small cell lung cancer (…

… Worldwide, the majority of patients with advanced non–small-cell lung cancer (… receptor
(EGFR). These wild-type patients comprise a significant proportion of those treated with inhibitors …

… results suggest that inhibition of FGFR kinase activity, while improving response to classic
therapeutic agents, could be efficient as a monotherapy for a subset of lung cancer patients. …

… Thus, combined HDAC inhibitor and gefitinib treatment represents a novel pharmacologic
strategy for overcoming resistance to EGFR inhibitors in patients with lung cancer. (Cancer …

… small cell lung cancer (NSCLC) and can be coexpressed with other members of the HER
receptor family to form functional heterodimers. We therefore investigated lung cancer cell lines …